Showing papers by "Joao Victor Machado Alessi published in 2017"

TL;DR: Monitoring of patients with EGFR-exon19del positive NSCLC and quantification of the original EGFR activation mutation, instead of the resistance mutations, can be efficiently used to monitor response to osimertinib, allowing early detection of AR.